生长抑素受体2（Somatostatin Receptor 2， SSTR2）是一类G蛋白偶联受体（GPCR）,其天然配 体是生长抑素（SST） [5]。 它是一种碱性稳定亲水性蛋白，无信号肽，存在7个跨膜区，作用于质膜结构 （图 2） [1]。 二级结构主要为α-螺旋，属7tm GPCRs超家族。 SSTR2基因及其编码蛋白在进化上高度保守，参 与调控G蛋白偶联受体信号通路。 SSTR2是唯一一种有SSTR2a和SSTR2b这2种异构体的SSTR亚型受体蛋白 [6]。 通过 STRING蛋白网络互作分析，SSTR2相 …

2022年9月22日 · Here we show that SSTR2 and SSTR5 but not SSR1, SSTR3 and SSTR4 can couple to the G q/11 pathway and that smaller ligands lead to the selective G i/o signaling of SSTR2 and SSTR5.

2024年12月25日 · SSTR2 (Somatostatin Receptor 2) is a Protein Coding gene. Diseases associated with SSTR2 include Neuroendocrine Tumor and Acromegaly. Among its related pathways are Class A/1 (Rhodopsin-like receptors) and GPCR downstream signalling.

We tested whether SSTR2 expression might contribute to tumor progression through activation of downstream signaling pathways, using in vitro and in vivo systems and down regulated SSTR2 expression in lung cancer cells by shRNA.

Our bioinformatic analysis revealed several SSTR2-related genes and signaling pathways in glioma. Most of the related genes were significantly associated with better survival in patients with glioma, as validated by the TCGA dataset.

Somatostatin receptor (SSTR) 2, widely expressed in meningioma, is a G-protein-coupled receptor and can be activated by somatostatin or its synthetic analogs. SSTR2 is therefore extensively studied as a marker and target for the diagnosis and treatment of meningioma.

2024年11月26日 · 近日，赛诺菲公司联合投资2000万美元，获得了Zucara Therapeutics公司“首创”靶向SSTR2的1型糖尿病新药ZT-01的优先谈判权。 ZT-01是一款生长抑素2型 (SSTR2)受体拮抗剂，能够预防使用胰岛素疗法的人发生低血糖，具有潜在“同类首创”的作用机理。 1b期概念验证试验显示，近90%的受试者在服用ZT-01后胰高血糖素显著增加，与安慰剂相比，采用3 mg和20 mg ZT-01分别导致峰值胰高血糖素相对于基线平均变化14 pg/mL和20 pg/mL（p<0.0001）。 该融 …

2024年1月1日 · This study aims to provide a comprehensive overview of SSTR2 expression patterns, prognostic implications, distinctive signaling pathways, epigenetic modifications, and potential therapeutic strategies associated with SSTR2 in HNSCC.

2019年3月1日 · We tested whether SSTR2 expression might contribute to tumor progression through activation of downstream signaling pathways, using in vitro and in vivo systems and downregulated SSTR2 expression in lung cancer cells by shRNA.

The SSTR2-mediated anti-proliferation involved both cytostatic (growth arrest) and cytotoxic (apoptotic) actions by affecting the cellular levels of signaling molecules in apoptotic pathway, MAPK pathway and angiogenesis.